NAPO PHARMS INC
PharmaNAPO PHARMS INC is a pharmaceutical company focused on Infectious Disease. Key products include MYTESI.
NAPO PHARMS INC's Key Drugs
NAPO PHARMS INC's core commercial portfolio centers on MYTESI, spanning Infectious Disease — its most strategically important drugs approved in the last 15 years.
NAPO PHARMS INC's Recent FDA Approvals
New NDA/BLA approvals for NAPO PHARMS INC over the last two years — novel drugs only, excluding generics and label supplements.
NAPO PHARMS INC's Therapeutic Areas
NAPO PHARMS INC's approved drugs and pipeline span 1 therapeutic area, led by Infectious Disease, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
NAPO PHARMS INC's Top Competitors
NAPO PHARMS INC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
NAPO PHARMS INC Pipeline Snapshot
Active clinical trials for NAPO PHARMS INC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • MYTESI leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2012-12-31
- Latest
- 2024-04-03
- Applications
- 1